Embryo Growth Disorder, Infertility, in Vitro Fertilization, Poor Ovarian Reserve
Conditions
Brief summary
Patients will have ovarian PRP treatments and embryo development will be observed using time-lapse imaging and AI software.
Detailed description
. oPRP Treatment & Second IVF Cycle (Study Cycle) * Following the first IVF cycle, patients will undergo their first oPRP injection: * Timing: 1-2 weeks after the onset of the next menstrual cycle. * Procedure: Under IV sedation, a patient's autologous PRP will be prepared and injected directly into both ovaries under transvaginal ultrasound guidance. * Second IVF Cycle (oPRP Study Cycle) * The same ovarian stimulation protocol will be used for consistency. * A second oPRP injection will be performed on stimulation days 2-5 to enhance folliculogenesis. * Ovulation will be triggered at the same follicular size thresholds, and oocyte retrieval will follow identical protocols. * Fertilization methodology will be identical to the first cycle unless no fertilization is identified in the first cycle. * Embryo Development Analysis: Up to 15 embryos will be cultured in the AI incubator, where time-lapse imaging will track their morphokinetics, and AI-based analysis will assess embryo viability and implantation potential.
Interventions
PROCEDUREOvarian Platelet-rich plasma (PRP) injections
This is a procedure that our patients receive at our clinic. We want to use the AI software to evaluate embryo development before and after treatment to see if there is a difference in embryo quality after PRP treatment within the same patient.
Sponsors
Generation Next Fertility
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
A NON-RANDOMIZED PROSPECTIVE SELF-CONTROLLED INTERVENTIONAL STUDY
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 47 Years
Healthy volunteers
Yes
Inclusion criteria
* No none contraindications to IVF or PRP treatment * Adequate ovarian reserves and AMH level * Willingness to undergo two IVF cycles and oPRP treatment
Exclusion criteria
* Anovulation due to menopause or perimenopause * Any health conditions that are contraindicated for IVF or oPRP treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Blastocyst formation and embryo quality | 1 year | The number of high quality embryos that are created per cycle |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Live birth rate per transfer | 2 years | The number of live births following embryo transfer |
Countries
United States
Contacts
Primary ContactAlicia L Broussard, PhD
Backup ContactJesse Hade, MD
Outcome results
None listed